For this year’s post-ASCO Lung Cancer panel discussion, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center, and Founder and President of GRACE, Christine Lovly, Associate Professor of Medicine, Division of Hematology-Oncology, and Dr. Alfredo Addeo, Medical Oncologist, department of Oncology at the University Hospital of Geneva (HUG), discuss the most current and emerging treatment information recently presented at ASCO. Drs. West, Lovly, and Addeo review key information from 2023 ASCO on lung cancer developments, including the results of several trials. In this video, Drs. West, Lovly, and Addeo discuss the CheckMate 9LA study, and treatment regimen options…
Author: Editor
For this year’s post-ASCO Lung Cancer panel discussion, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center, and Founder and President of GRACE, Christine Lovly, Associate Professor of Medicine, Division of Hematology-Oncology, and Dr. Alfredo Addeo, Medical Oncologist, department of Oncology at the University Hospital of Geneva (HUG), discuss the most current and emerging treatment information recently presented at ASCO. Drs. West, Lovly, and Addeo review key information from 2023 ASCO on lung cancer developments, including the results of several trials. In this video, Drs. West, Lovly, and Addeo discuss their questions surrounding adjuvant immunotherapy. For more, please…
For this year’s post-ASCO Lung Cancer panel discussion, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center, and Founder and President of GRACE, Christine Lovly, Associate Professor of Medicine, Division of Hematology-Oncology, and Dr. Alfredo Addeo, Medical Oncologist, department of Oncology at the University Hospital of Geneva (HUG), discuss the most current and emerging treatment information recently presented at ASCO. Drs. West, Lovly, and Addeo review key information from 2023 ASCO on lung cancer developments, including the results of several trials. In this video, Drs. West, Lovly, and Addeo discuss the Keynote 671 study, which examined the use…
For this year’s post-ASCO Lung Cancer panel discussion, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center, and Founder and President of GRACE, Christine Lovly, Associate Professor of Medicine, Division of Hematology-Oncology, and Dr. Alfredo Addeo, Medical Oncologist, department of Oncology at the University Hospital of Geneva (HUG), discuss the most current and emerging treatment information recently presented at ASCO. Drs. West, Lovly, and Addeo review key information from 2023 ASCO on lung cancer developments, including the results of several trials. In this video, Drs. West, Lovly, and Addeo discuss potential flaws with the ADAURA trial, but also…
For this year’s post-ASCO Lung Cancer panel discussion, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center, and Founder and President of GRACE, Christine Lovly, Associate Professor of Medicine, Division of Hematology-Oncology, and Dr. Alfredo Addeo, Medical Oncologist, department of Oncology at the University Hospital of Geneva (HUG), discuss the most current and emerging treatment information recently presented at ASCO. Drs. Drs. West, Lovly, and Addeo discuss the ADAURA trial, which studied patients with resected or resectable stage IB-IIIA EGFR+ NSCLC who were given Tagrisso. In this video, Drs. West, Lovly, and Addeo discuss the ADAURA trial, which…
For this year’s post-ASCO Lung Cancer panel discussion, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center, and Founder and President of GRACE, Christine Lovly, Associate Professor of Medicine, Division of Hematology-Oncology, and Dr. Alfredo Addeo, Medical Oncologist, department of Oncology at the University Hospital of Geneva (HUG), discuss the most current and emerging treatment information recently presented at ASCO. Drs. West, Lovly, and Addeo review key information from 2023 ASCO on lung cancer developments, including the results of several trials. In this video, Drs. West, Lovly, and Addeo discuss the FANSS study, which screened Asian never-smoking women…
KEY TAKEAWAYS: Ribociclib, a CDK4/6 inhibitor, is a promising drug in the treatment of early-stage and metastatic breast cancer, particularly when used in combination with endocrine therapy. The NATALEE study underscores the efficacy of Ribociclib, demonstrating a significant reduction in disease recurrence. Despite potential side effects, Ribociclib contributes to improved survival rates and quality of life for breast cancer patients. Future studies aim to explore the long-term outcomes of Ribociclib and potential combination therapies, illuminating new paths in breast cancer treatment. With advancements like Ribociclib, the future of breast cancer treatment looks promising, bringing hope to patients worldwide. Breast cancer…
Lung cancer screening has emerged as an essential tool in identifying the disease at its early stages, when it is most treatable. However, despite the potential benefits, screening rates for lung cancer remain alarmingly low across the United States. The Importance of Lung Cancer Screening for Early Detection Lung cancer screening aims to identify lung cancer in its initial stages, even before symptoms manifest, through the use of various diagnostic tests. Challenges Faced in Lung Cancer Screening Rates Across the US Despite the proven benefits of lung cancer screening, there are several challenges that hinder widespread implementation. Low awareness among…
Clinical trials, as many are aware, often face numerous failures. Countless molecules are tested before finding a successful one. Anju, as a company, is dedicated to utilizing technology to safely expedite clinical trials with maximum information, validation, and efficacy. Their objective is to ensure both quick failures and successful outcomes in order to bring exceptional products to market. Laurence Birch, Chief Executive Officer of Anju, discusses how Anju works closely with oncology sponsors and contract research organizations (CROs), collaborating hand in hand to accelerate trials safely. The COVID-19 pandemic has significantly accelerated the use of technology, particularly in the field…
Gliomas are a complex group of brain and spinal cord tumors that start from glial cells, which are cells that support the health of the nervous system. Gliomas can range in severity, with the term “high-grade gliomas” often used to describe the most aggressive and dangerous forms of this cancer. High-grade gliomas are noted for their rapid growth and their proclivity to infiltrate surrounding brain tissue, making them a significant challenge to treat. A specific type of high-grade glioma that you may have heard about is Glioblastoma, which is the deadliest type of brain cancer. A promising study, titled “Safety…
BRAF V600E colon cancer is a subtype of colorectal cancer characterized by a specific genetic mutation known as BRAF V600E. This mutation plays a crucial role in the development and progression of the disease, making it a topic of significant interest in the field of oncology. In recent years, targeted therapy has emerged as a groundbreaking approach in treating various types of cancer, including BRAF-mutated colorectal cancer. Unlike traditional chemotherapy, which affects both healthy and cancerous cells, targeted therapy focuses on specific genetic or molecular abnormalities within cancer cells, aiming to inhibit their growth and spread. One notable clinical trial…
TROPiCS-02 Trial: The TROPiCS-02 trial showcases the potential of Sacituzumab Govitecan, a Trop-2 directed antibody-drug conjugate, as a promising treatment for HR+/HER2– metastatic breast cancer. Improved Survival Rates: The trial results demonstrate a significant improvement in overall survival rates for patients treated with Sacituzumab Govitecan. A New Approach: The trial represents a novel approach in treating metastatic breast cancer by targeting Trop-2, a cell surface protein overexpressed in several cancers. Navigating the complex world of oncology can be overwhelming, especially when it comes to understanding the myriad of treatment options available. One critical area of focus is Metastatic Breast Cancer…
Dr. Jack West, MD, an associate professor in medical oncology focused on thoracic oncology at the City of Hope Comprehensive Cancer Center in Los Angeles, addresses the highlights of ASCO 2023 lung cancer. He discussed his top five abstracts in the field. The first abstract was the ADAURA trial, which showed improved overall survival with adjuvant osimertinib in EGF mutation-positive resectable disease. The second abstract was Keynote 671, which explored perioperative chemo with pembrolizumab in lung cancer patients. Keynote 789, the third abstract, was a trial of chemo with pembrolizumab for patients with acquired resistance to EGF mutation-positive disease. …
Abemaciclib, a CDK4 & 6 inhibitor, has shown a sustained benefit in invasive disease-free survival in high-risk EBC, as seen in the monarchE trial. While effective, abemaciclib does have side effects, and these can be more pronounced in older patients. Diarrhea, fatigue, and neutropenia are among the common adverse events. Older patients require careful monitoring. They may require more frequent surveillance and early intervention to manage adverse events, particularly those above 75 years of age. The monarchE trial represents a significant step forward in the fight against breast cancer. Its results offer an evidence-based approach to improving patient outcomes. Individualized…
Thromboembolism are highly prevalent and burdensome in patients with cancer. Risk for venous thromboembolism (VTE) varies widely across specific cancer patients. The ability to predict risk of cancer-associated VTE is critical because for an optimal thromboprophylaxis strategy. This means targeting high-risk patients with cancer and avoiding prophylaxis in cancer patients at low risk for VTE. @sngilani
Chronic Lymphocytic Leukemia (CLL) is a serious condition, and the current standard treatment involves a combination of Ibrutinib and Obinutuzumab (IO). A new treatment approach, the combination of Ibrutinib, Venetoclax, and Obinutuzumab (IVO), shows promising results in clinical trials, potentially paving the way for a new standard in CLL treatment. The COVID-19 pandemic has had significant impacts on patients with CLL, emphasizing the importance of comprehensive disease management and prevention measures. Expert insights, such as those provided by Brian Hill MD, provide valuable context and understanding of the rapidly evolving field of CLL treatment. The potential to achieve undetectable minimal…
Welcome to our in-depth exploration of a topic of big importance in the field of oncology: Metastatic Castration-Resistant Prostate Cancer (mCRPC). Prostate cancer is a prevalent form of cancer in men around the world. The American Cancer Society predicts that in the United States alone, there will be approximately 288,300 new cases of prostate cancer in 2023, making it an important topic for awareness and research. The prostate, a small gland that produces seminal fluid in men, can sometimes become the breeding ground for malignant cells, leading to prostate cancer. It can manifest with various symptoms such as: Difficulty in…
Prithvi Bose, an associate professor in the Department of Leukemia at MD Anderson Cancer Center in Houston, Texas, focuses on Myeloproliferative neoplasms and specifically addresses the management of anemia in myelofibrosis. Anemia is a common and significant clinical presentation that poses a burden on both patients and the healthcare system. Approximately one-third of myelofibrosis patients present with anemia, and eventually, all patients develop anemia. Anemia has been recognized as an unfavorable prognostic factor and is included in various prognostic models for myelofibrosis. The severity of anemia impacts survival, and transfusion requirements also affect prognosis. Current approaches to managing anemia in…
Today we talk about a topic that has been stirring considerable interest in the oncology field, promising an innovative approach to tackling Grade 2 glioma, a type of slowly progressive malignant brain tumor. When it comes to understanding what is the Indigo trial?, we need to delve into the complex world of oncology, genetics, and drug development. At its core, the Indigo Trial is a phase 3 clinical study testing the efficacy of an experimental drug called Vorasidenib in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation. The trial has been designed to assess whether this…
Refractory multiple myeloma remains a significant challenge in the field of oncology, necessitating innovative therapeutic strategies. Mezigdomide, a novel oral cereblon E3 ligase modulator, exhibits potential in treating RRMM due to its unique mechanism of action. The SUCCESSOR-2 trial, comparing MeziKd vs Kd, promises valuable insights into the efficacy and safety of mezigdomide. When it comes to navigating the intricacies of oncology, refractory multiple myeloma (RRMM) presents a significant hurdle. Multiple myeloma (MM), a cancer of plasma cells, usually responds well to initial treatment, leading to remission. However, in many instances, the disease recurs, becoming more resistant to the standard…
Pembrolizumab plus Lenvatinib, individually known for their robust anti-cancer mechanisms, when combined, show significant promise in treating advanced renal cell carcinoma. The KEYNOTE-581 trial revealed significant improvements in survival outcomes with pembrolizumab/lenvatinib, demonstrating its potential as a first-line treatment for advanced renal cell carcinoma. However, potential immune-mediated adverse reactions and other complications linked to this treatment combination require careful monitoring and management. The promising results of this study also hint at potential applications of this drug combination for other types of cancer, but more extensive research is needed. Despite the potential side effects, the combination of pembrolizumab and lenvatinib signals…
In ASCO 2023, the highly anticipated results of the Adora study were unveiled, providing valuable insights into the efficacy and impact of adjuvant osimertinib in patients with resected stage one to stage three non-small cell lung cancer (NSCLC). This study presented the final overall survival data, complementing the previously reported disease-free survival data from 2020. The findings, which were presented in the plenary session, shed light on the remarkable potential of osimertinib in improving patient outcomes and redefining treatment approaches for NSCLC. The Adora Study The Adora study was designed to investigate the efficacy of adjuvant osimertinib in patients with resected…
… Metastatic colorectal cancer (mCRC) continues to be a significant health challenge worldwide. Despite advancements in treatment methods, the prognosis for patients with mCRC remains poor, with a 5-year survival rate of only 14% according to the American Cancer Society. Current treatment options such as regorafenib or trifluridine-tipiracil offer limited benefits, emphasizing the urgent need for innovative therapeutic approaches. One such promising avenue of research involves the use of novel multi-kinase inhibitors (MKIs) in combination with immune checkpoint inhibitor (ICI) therapies. This article will delve into an ongoing phase 3 clinical trial named STELLAR-303, which is assessing the efficacy and…
Vorasidenib (AG-881) is a promising targeted therapy for gliomas with IDH1 or IDH2 mutations. This novel approach could potentially revolutionize glioma treatment, reducing side effects and improving outcomes. Gliomas, specifically Grade 2 gliomas, are a complex group of brain tumors with varying prognoses depending on factors like the IDH1 or IDH2 mutation status. The INDIGO trial aims to evaluate the effectiveness of Vorasidenib for treating Grade 2 gliomas. Initial results show improved overall survival and progression-free survival. The insights from Karan Dixit MD during ASCO 2023 offer a detailed look into the potential of Vorasidenib and the hope it presents…
FOTIVDA is Aveo’s marketed product for treating advanced renal cell carcinoma, primarily used as a later line agent in the management of metastatic disease. The ongoing TiNivo-2 study aims to compare the efficacy of FOTIVDA alone, administered at its approved dose, with FOTIVDA in combination with nivolumab, a checkpoint inhibitor developed by Bristol-Myers Squibb. The study is expected to complete accrual soon, with results anticipated within the next year or year and a half.With LG’s support, Aveo has embarked on exploring the potential of FOTIVDA in other indications through sponsored studies and investigator-initiated trials. They are particularly interested in investigating…
Sotorasib, as demonstrated by the CodeBreaK 200 study, is a promising treatment for patients with KRAS G12C-mutated advanced NSCLC, with superior progression-free survival and an overall response rate compared to docetaxel. Biomarkers play an integral role in determining the path of personalized medicine, offering a glimpse into a future where cancer treatment is custom-made according to each patient’s genetic makeup. The CodeBreaK 200 study is a significant milestone in oncology research, but the journey doesn’t end here. Continuous research promises further breakthroughs to improve outcomes for NSCLC patients. As we delve into the era of precision medicine, targeted therapies are…
Vorasidenib, an oral, brain-penetrant, dual inhibitor of mutant IDH1/2 enzymes, shows promise in treating grade 2 gliomas. The INDIGO trial, a phase 3 study, demonstrates the clinical benefit of vorasidenib, significantly improving progression-free survival compared to placebo. This research paves the way for the rise of personalized medicine in oncology, highlighting the role of targeted therapies in managing cancer. The potential impact on grade 2 glioma treatment is significant, with vorasidenib offering a novel treatment option that may improve patient prognosis and quality of life. The future of glioma treatment seems promising, with vorasidenib’s success encouraging continued research and development…
… The battle against cancer has led to a myriad of innovations in oncology, with each new breakthrough providing a beacon of hope for those grappling with this often devastating disease. One such innovation is fruquintinib, a promising drug that has emerged in the realm of targeted cancer therapy. This article is focus on the specifics of fruquintinib and its role in the much-discussed FRESCO-2 study. Developed to be highly selective and potent, fruquintinib is a tyrosine kinase inhibitor (TKI) designed to block the vascular endothelial growth factor receptors (VEGFRs) -1, -2, and -3, known to play pivotal roles in…
Infigratinib, an FGFR1-3 inhibitor, has shown promise as an adjuvant therapy for invasive urothelial carcinoma. The FDA has approved infigratinib (Truseltiq) for the treatment of previously treated, FGFR2 fusion or other rearrangement-positive cholangiocarcinoma. Urothelial carcinoma is a common form of urinary tract cancer. When invasive, it can lead to serious health complications. FGFR3 alterations are common in invasive urothelial carcinoma and may serve as significant biomarkers for patient stratification and targeted therapy. The PROOF 302 study suggests infigratinib could significantly improve disease-free survival in patients with FGFR3-altered invasive urothelial carcinoma. Pembrolizumab is another valuable treatment option for urothelial carcinoma, providing…
Constantinos Savva, MD, M.Sc., PGDip, MRCP, SCE, from the University of Southampton conducted a study on the effects of metformin, a commonly used diabetes medication, on the immune cell composition within breast cancer tumors. The study aimed to investigate whether metformin could modulate immune cell dysfunction caused by chronic inflammation in breast cancer patients. The researchers conducted two separate peri-surgical window studies, one in Dundee (with 29 patients) and another in Oxford (with 31 patients). They analyzed tissue samples using immunohistochemistry to identify specific immune cell markers before and after metformin treatment. The densities of immune cell infiltrates were quantified…
Michael Chuong, MD, from Baptist Health has conducted a Phase 2 trial on the use of ablative MRI-guided stereotactic body radiation therapy (SBRT) combined with tumor treating fields (TTF) for the treatment of locally advanced pancreas cancer. The study aimed to evaluate the effectiveness and safety of this novel approach in improving outcomes for patients with this challenging disease. Pancreas cancer is known for its aggressive nature and limited treatment options, particularly in locally advanced cases where the tumor has spread to nearby tissues and organs. Traditional treatment approaches such as surgery and chemotherapy have shown limited success in achieving…
Philip McCarthy, MD, from Roswell Park Cancer Institute provided an overview of CAR T-cell therapy, focusing on its application in multiple myeloma. CAR T-cell therapy involves genetically modifying T-cells to express a chimeric antigen receptor (CAR) that recognizes a specific antigen on tumor cells, such as BCMA (B-cell maturation antigen). The therapy takes advantage of the cytotoxic potential of T-cells to kill tumor cells in an antigen-dependent manner. The first clinical trial of CAR T-cell therapy was conducted in patients with resistant chronic lymphocytic leukemia in 2011. Since then, the therapy has shown promise in multiple myeloma, particularly in patients…
Cody Peer, PhD, from the National Institutes of Health, is conducting a randomized research study comparing the dosing intervals of two drugs, nivolumab and pembrolizumab, in patients with locally advanced or metastatic cancers. The study aims to determine if these drugs can be administered less frequently than the currently approved dosing schedule. The primary outcome measure of the study is the noninferiority of extended interval dosing compared to standard dosing. The researchers will evaluate the drug trough levels in the blood and categorize patients as either successful or unsuccessful based on achieving drug trough levels above the target concentration of…
Manojkumar Bupathi, MD, from the Rocky Mountain Cancer Centers, conducted a study to evaluate the effectiveness of sacituzumab govitecan (SG) in patients with locally advanced (LA) or metastatic urothelial cancer (mUC) based on the expression of trophoblast cell surface antigen 2 (Trop-2). The study aimed to determine if Trop-2 expression levels could predict response to treatment. Trop-2 is a glycoprotein that is often highly expressed in various cancers, including urothelial cancer. SG is an antibody-drug conjugate that specifically targets Trop-2. It has been approved by the FDA for use in patients with LA unresectable or mUC who have previously received…
KEYNOTE-716 trial brings to light the impressive efficacy of pembrolizumab as an adjuvant therapy for stage IIB or IIC melanoma. Pembrolizumab significantly reduces the risk of disease recurrence or death, offering a promising treatment strategy for high-risk melanoma patients. Despite some side effects, pembrolizumab presents a manageable safety profile, making it a viable long-term treatment option. These compelling findings bolster the potential role of immune checkpoint inhibitors in various stages and types of cancer. Melanoma cancer, a potentially deadly form of skin cancer, is a global concern, with its incidence rates steadily on the rise over the past decades. As…
Anthony Stein, MD, from the City of Hope, has conducted a first-in-human study to evaluate the safety and efficacy of a new treatment called CD123 NK Cell Engager SAR443579 in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia. The study aimed to assess the drug’s ability to activate natural killer (NK) cells and target cancer cells expressing the CD123 antigen. SAR443579 is designed to engage both NKp46 and CD16a receptors on NK cells, forming a cytolytic synapse with CD123-positive tumor cells. This interaction leads to the activation of NK cells, resulting…
The Impact of ASCO 2022 on Oncology In the ever-evolving field of oncology, ASCO 2022 stands out as a landmark event, showcasing the latest advancements and research findings in cancer care. The American Society of Clinical Oncology (ASCO) Annual Meeting provides a global platform for researchers, practitioners, and patients alike to share insights, learn from each other, and push the boundaries of our understanding of cancer. ASCO is an internationally acclaimed congregation, highlighting cutting-edge scientific research and fostering collaboration among global oncology stakeholders. The ASCO 2022 meeting played host to a multitude of studies, spanning various aspects of cancer research.…
Majid Jaberi-Douraki, PhD from Kansas State University, and Shahzad Raza, MD from the Cleveland Clinic, conducted a study to evaluate global disparities in multiple myeloma (MM) through data mining of the FDA Adverse Event Reporting System (FAERS). The study aimed to assess adverse events (AEs) associated with FDA-approved MM drugs from 2003 to 2022 and stratify patient data based on age, sex, and geographical regions. The researchers analyzed data from 381,378 MM patients across North America (NA), Europe (EU), Asia (AS), Africa (AF), Oceania (OC), and Latin America & the Caribbean (LA), sourced from 129 countries. They focused on AEs…
Manojkumar Bupathi, MD, MS, from Rocky Mountain Cancer Centers, conducted a safety analysis on cohort 1 of the TROPHY-U-01 phase 2 study. The study evaluated the use of sacituzumab govitecan (SG) in patients with metastatic urothelial cancer (mUC) who had experienced disease progression after receiving platinum-based chemotherapy and a checkpoint inhibitor (CPI). The safety analysis specifically focused on the UGT1A1 status of the patients. The study included a total of 113 patients who were administered SG as a treatment for mUC. UGT1A1 is a gene responsible for the metabolism of irinotecan, a component of SG. Variations in the UGT1A1 gene…
Ismael Rodriguez Rivera, MD, Medical Oncologist and Clinical Investigator from NEXT Oncology, has conducted a groundbreaking study on a novel therapeutic approach for patients with advanced or metastatic solid tumors. The study, titled “CBX-12-101: A first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients with advanced or metastatic solid tumors,” focuses on evaluating the safety and efficacy of CBX-12, an innovative alphalex peptide drug conjugate. The study conducted by Dr. Rodriguez Rivera represents the first time CBX-12 has been administered to human subjects. Alphalex peptide drug conjugates (PDCs) are a new class of targeted therapeutics designed to…
Advanced Urothelial carcinoma, primarily affecting the urinary system, is a typically aggressive cancer with limited treatment options. Pembrolizumab, an immunotherapy drug, has shown promise as an effective monotherapy for advanced urothelial carcinoma. The KEYNOTE-045 and KEYNOTE-361 trials demonstrated the efficacy and safety of pembrolizumab irrespective of the histological subtype of urothelial carcinoma. Despite the limitations in these trials, the findings hold substantial implications for the treatment of advanced urothelial carcinoma, potentially paving the way for personalized cancer therapy. Ongoing research and clinical trials are necessary to further establish the full potential of pembrolizumab and explore other emerging therapies. The complex…
Erika Hamilton, MD, a preeminent expert from the Sarah Cannon Research Institute, has recently conducted a study evaluating the efficacy and safety of adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR-positive, HER2-negative, node-positive, high-risk early breast cancer (EBC), with a focus on analyzing the results based on age groups. The study, known as monarchE, aimed to provide valuable insights into the treatment outcomes of this specific patient population. In the monarchE study, Dr. Hamilton and her team enrolled a diverse group of patients diagnosed with HR-positive, HER2-negative, node-positive EBC, which is considered a high-risk subtype. The patients…
Nadia Harbeck, MD, PhD, from the University of Münster, recently conducted a primary outcome analysis of the multicenter randomized PreCycle trial, evaluating the impact of CANKADO PRO-React eHealth support on patients with HR+ HER2- metastatic breast cancer receiving palbociclib and endocrine therapy. The primary objective of the study was to assess the effect of eHealth support on the time to deterioration of quality of life in these patients. The PreCycle trial included a total of 234 patients who were randomly assigned to either the intervention group or the control group. The intervention group received the CANKADO PRO-React eHealth support in…
Roy Herbst, MD, PhD, from the Yale Cancer Center and Yale School of Medicine, presented a groundbreaking abstract at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The abstract, titled “Final ADAURA OS Analysis Reinforces Adjuvant Osimertinib as a Standard of Care for Patients With Stage IB to IIIA EGFR-Mutated Non–Small Cell Lung Cancer,” highlights the significant impact of adjuvant osimertinib in the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC) in stages IB to IIIA. The study presented by Dr. Herbst is based on the results of the ADAURA trial, which is a randomized, double-blind,…
Non-Small Cell Lung Cancer (NSCLC) is a complex and aggressive form of lung cancer, but developments in treatments and therapies provide a beacon of hope. The LUNAR Phase 3 Clinical Trial by Novocure has shown significant and clinically meaningful improvement in overall survival for NSCLC patients when TTFields therapy is added to standard pharmacological therapies. Novocure’s Tumor Treating Fields (TTFields) therapy is a ground-breaking approach in cancer treatment, using electric fields to selectively target and kill cancer cells, sparing healthy ones. Continuous research and clinical trials are key to better understanding NSCLC, improving treatments, and increasing life expectancy for patients.…
Brexucabtagene autoleucel (Tecartus) is a ground-breaking CAR T-cell therapy for the treatment of relapsed or refractory mantle cell lymphoma. The ZUMA-2 trial demonstrated the high efficacy of brexucabtagene autoleucel, which led to its accelerated approval by the FDA. Real-world studies like the CIBMTR subgroup analysis continue to validate the efficacy of brexucabtagene autoleucel across diverse patient populations and treatment lines. Direct insights from leading experts like Dr. Swetha Kambhampati at ASCO 2023 provide an in-depth understanding of brexucabtagene autoleucel’s real-world outcomes. The use of brexucabtagene autoleucel in earlier lines of therapy may yield higher complete response rates. Ongoing research and…
Caicun Zhou, MD, PhD – Tongji University Shanghai Pulmonary Hospital Sunvozertinib established itself as the leading targeted therapy for NSCLC patients with EGFR Exon20ins mutations, demonstrating unprecedented response rates and potential for first-line treatment. Sunvozertinib, a targeted therapy, has emerged as a “Best-in-Class” treatment for non-small cell lung cancer (NSCLC) patients with EGFR Exon20 insertion (Exon20ins) mutations, which typically have poor outcomes. The drug has shown remarkable efficacy, with an objective response rate (ORR) of 60.8% in the second-line setting and beyond. Additionally, sunvozertinib demonstrated a high ORR of 77.8% in treatment-naive patients, indicating its potential as a superior…
Ian Krop, MD, PhD – Yale University This study conducted an age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (mBC) using data from the DESTINY-Breast01, -02, and -03 trials. The analysis aimed to evaluate the efficacy and safety of T-DXd across different age groups. The results provide valuable insights into the use of T-DXd in HER2-positive mBC patients of varying ages.
Ian B. Walters, MD – Portage Biotech Inc The IMPORT-201 study investigates the use of IMM60, a novel iNKT agonist, in combination with pembrolizumab for advanced melanoma and metastatic non-small cell lung cancer (NSCLC). Preclinical studies have shown promising results, including tumor regression and immune activation. Initial results from the phase 1 portion of the study demonstrate that IMM60, as monotherapy and in combination with pembrolizumab, is well-tolerated and shows potential in inducing positive treatment responses, warranting further investigation in heavily pretreated patients.
Jonathan David Tward ,MD, PHD, FASTRO – University of Utah A study using the Prolaris test shows that it can accurately predict the personalized absolute benefit and number-needed-to-treat (NNT) for patients receiving androgen deprivation therapy (ADT) added to radiation therapy (RT) in newly diagnosed prostate cancer. By assessing the clinical cell-cycle risk (CCR) score, the study determined that patients with CCR scores above a prespecified multimodality treatment threshold (MTT) had a higher absolute benefit of ADT treatment (8.2% with NNT=12) compared to those below the MTT (0.86% with NNT=116). These findings provide valuable insights for personalized decision-making regarding the use…